Literature DB >> 21188426

Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis.

Takashi Tomiyama1, Kazushige Uchida, Mitsunobu Matsushita, Tsukasa Ikeura, Toshiro Fukui, Makoto Takaoka, Akiyoshi Nishio, Kazuichi Okazaki.   

Abstract

BACKGROUND: The efficacy of oral steroid therapy for autoimmune pancreatitis (AIP) is well known, and oral prednisolone treatment is most usually commenced at 30-40 mg/day, but there have been few reports about comparative studies of oral steroid therapy and steroid pulse therapy as the initial treatment for AIP. We studied the clinical course and image findings to estimate the utility of steroid pulse therapy for AIP, comparing it with oral steroid therapy.
METHODS: Laboratory and image findings were assessed retrospectively in 11 patients who received steroid pulse therapy, and the findings were compared to those in 10 patients who received conventional oral steroid therapy.
RESULTS: Change in pancreatic size showed no significant difference between the therapies after 2 weeks of treatment. Significant improvement of lower bile duct strictures after 2 weeks of treatment and that of immunoglobulin values within 6 months were shown with both therapies. However, steroid pulse therapy showed significant improvement of γ-guanosine triphosphate (GTP) in 2 weeks and of alanine aminotransferase (ALT) in 2 and 8 weeks, compared with oral steroid therapy. Moreover, there was one patient in whom the lower bile duct stricture was not improved by oral steroid therapy, but it did show improvement with steroid pulse therapy.
CONCLUSIONS: Initial steroid pulse therapy is a beneficial alternative to oral steroid therapy for the improvement of bile duct lesions. In future, the accumulation of a larger number of patients receiving steroid pulse therapy is needed, and prospective studies will be required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188426     DOI: 10.1007/s00535-010-0361-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  39 in total

1.  Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis.

Authors:  Mitsunobu Matsushita; Masao Yamashina; Tsukasa Ikeura; Massaki Shimatani; Kazushige Uchida; Makoto Takaoka; Kazuichi Okazaki
Journal:  Am J Gastroenterol       Date:  2007-01       Impact factor: 10.864

2.  Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan.

Authors:  Isao Nishimori; Akiko Tamakoshi; Shigeyuki Kawa; Shigeki Tanaka; Kazuo Takeuchi; Terumi Kamisawa; Hiromitsu Saisho; Kenji Hirano; Keiya Okamura; Nobuyuki Yanagawa; Makoto Otsuki
Journal:  Pancreas       Date:  2006-04       Impact factor: 3.327

3.  Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy?

Authors:  Mitsunobu Matsushita; Tsukasa Ikeura; Toshiro Fukui; Kazushige Uchida; Kazuichi Okazaki
Journal:  Am J Gastroenterol       Date:  2008-07       Impact factor: 10.864

4.  Adrenal atrophy and irreversible shock associated with cortisone therapy.

Authors:  C G FRASER; F S PREUSS; W D BIGFORD
Journal:  J Am Med Assoc       Date:  1952-08-23

5.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 6.  Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors:  K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

7.  Early bile duct cancer in a background of sclerosing cholangitis and autoimmune pancreatitis.

Authors:  Hyoung-Chul Oh; Jae Gyu Kim; Jeong Wook Kim; Kwang Sun Lee; Mi Kyung Kim; Kyong Choun Chi; Yong Seok Kim; Ki Hyun Kim
Journal:  Intern Med       Date:  2008-12-01       Impact factor: 1.271

8.  Pancreatic cancer associated with autoimmune pancreatitis in remission.

Authors:  Toshiro Fukui; Toshiyuki Mitsuyama; Makoto Takaoka; Kazushige Uchida; Mitsunobu Matsushita; Kazuichi Okazaki
Journal:  Intern Med       Date:  2008-02-01       Impact factor: 1.271

9.  Standard steroid treatment for autoimmune pancreatitis.

Authors:  T Kamisawa; T Shimosegawa; K Okazaki; T Nishino; H Watanabe; A Kanno; F Okumura; T Nishikawa; K Kobayashi; T Ichiya; H Takatori; K Yamakita; K Kubota; H Hamano; K Okamura; K Hirano; T Ito; S B H Ko; M Omata
Journal:  Gut       Date:  2009-04-26       Impact factor: 23.059

10.  Morphological changes after steroid therapy in autoimmune pancreatitis.

Authors:  T Kamisawa; N Egawa; H Nakajima; K Tsuruta; A Okamoto
Journal:  Scand J Gastroenterol       Date:  2004-11       Impact factor: 2.423

View more
  13 in total

Review 1.  Clinical and pathophysiological issues associated with type 1 autoimmune pancreatitis.

Authors:  Kazushige Uchida; Hideaki Miyoshi; Tsukasa Ikeura; Masaaki Shimatani; Makoto Takaoka; Kazuichi Okazaki
Journal:  Clin J Gastroenterol       Date:  2016-02-10

2.  Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids.

Authors:  Kensuke Kubota; Seitaro Watanabe; Takashi Uchiyama; Shingo Kato; Yusuke Sekino; Kaori Suzuki; Hironori Mawatari; Hiroshi Iida; Hiroki Endo; Koji Fujita; Masato Yoneda; Hirokazu Takahashi; Hiroyuki Kirikoshi; Noritoshi Kobayashi; Satoru Saito; Kazuya Sugimori; Kantaro Hisatomi; Nobuyuki Matsuhashi; Hirotaka Sato; Emiko Tanida; Takashi Sakaguchi; Nobutaka Fujisawa; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2011-04-15       Impact factor: 7.527

3.  Oral steroid versus steroid pulse therapy for autoimmune pancreatitis: time to introduce new weapons.

Authors:  Ahad Eshraghian; Hamed Eshraghian
Journal:  J Gastroenterol       Date:  2011-09-20       Impact factor: 7.527

Review 4.  Autoimmune pancreatitis: pathogenesis, latest developments and clinical guidance.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Kimi Sumimoto; Toshiyuki Mitsuyama; Tsukasa Ikeura; Makoto Takaoka
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 5.  Diagnosis of IgG4-related sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Katsuyuki Miyabe; Shuya Simizu; Takashi Joh
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 6.  [IgG4-related disease].

Authors:  J Loock; B Manger
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

7.  A case of autoimmune pancreatitis effectively treated with an immunosuppressant (azathioprine).

Authors:  Akane Yamabe; Atsushi Irisawa; Kenji Notohara; Goro Shibukawa; Mariko Fujisawa; Ai Sato; Yoshitsugu Yoshida; Noriyuki Arakawa; Tsunehiko Ikeda; Ryo Igarashi; Takumi Maki; Shogo Yamamoto
Journal:  Clin J Gastroenterol       Date:  2016-07-23

8.  IgG4-related sclerosing cholangitis: not always an obvious entity.

Authors:  Magdalini Velegraki; Emmanouil Vardas; Christos Dervenis; Maria Fragaki; Pinelopi Nikolaou; Afroditi Mpitouli; George Kazamias; Athanasia Sepsa; Elpida Giannikaki; Gregorios A Paspatis
Journal:  Ann Gastroenterol       Date:  2021-02-26

9.  Efficacy of Steroid Pulse Therapy for Autoimmune Pancreatitis Type 1: A Retrospective Study.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Yuichi Waragai; Hiroyuki Asama; Mika Takasumi; Takuto Hikichi; Hiroshi Watanabe; Katsutoshi Obara; Hiromasa Ohira
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

10.  International Consensus Diagnostic Criteria for Autoimmune Pancreatitis and Its Japanese Amendment Have Improved Diagnostic Ability over Existing Criteria.

Authors:  Masahiro Maruyama; Takayuki Watanabe; Keita Kanai; Takaya Oguchi; Takashi Muraki; Hideaki Hamano; Norikazu Arakura; Shigeyuki Kawa
Journal:  Gastroenterol Res Pract       Date:  2013-11-21       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.